TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a primary diagnosis of ADHD~* Subject on a stable dose of a psychostimulant approved for the treatment of ADHD for at least 1 month, with sub-optimal control in the Investigator's opinion~* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements~Exclusion Criteria:~* Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD and mild anxiety) with significant symptoms~* History of seizure during the last 2 years~* Subject has any specific cardiac condition or family history of significant cardiac condition~* Subject is pregnant or lactating

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate + SPD503 (Type: EXPERIMENTAL): None
- Amphetamine + SPD503 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Raxone in LHON Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Impaired visual acuity in affected eyes due to LHON~2. No explanation for visual loss besides LHON~3. Age more or equal 12 years~4. Onset of symptoms ≤5 years of Baseline~5. Confirmation of either G11778A, G3460A or T14484C LHON mtDNA (for the Intent-to Treat (ITT) population, not required for enrolment)~6. Written informed consent obtained from the patient~7. Ability and willingness to comply with study procedures and visits~8. Women of Childbearing Potential (WCBP) who have a negative urine or serum pregnancy test at Baseline visit and who are willing to use a highly effective contraceptive measure and maintain it until treatment discontinuation.~Exclusion Criteria:~1. Patient has provided natural history data to the Case Record Survey (SNT-CRS-002)~2. Any previous use of idebenone~3. Any other cause of visual impairment (e.g. glaucoma, diabetic retinopathy, AIDS related visual impairment, cataract, macular degeneration, etc.) or any active ocular disorder (uveitis, infections, inflammatory retinal disease, thyroid eye disease, etc.)~4. Known history of clinically significant elevations (greater than 3 times the upper limit of normal) of aspartate aminotransferase (AST), alanine transaminase (ALT) or creatinine~5. Patient has a condition or is in a situation which, in an investigator's opinion may put the patient at significant risk, may confound study results or may interfere significantly with the patient's participation in the study~6. Participation in another clinical trial of any investigational drug within 3 months prior to Baseline~7. Hypersensitivity to the active substance or to any of the following excipients (as listed in section 6.1 of Raxone SmPC): Lactose monohydrate, Microcrystalline cellulose, Croscarmellose sodium, Povidone K25, Magnesium stearate, Colloidal silica, Macrogol 3350, Poly(vinyl alcohol), Talc, Titanium dioxide, Sunset yellow FCF (E110).~8. Women who are pregnant or have a positive pregnancy test at Baseline visit~9. Women who are breastfeeding

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raxone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 12 months~* P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection~* Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs~* Ability to swallow oral medication.~* Ability and willingness to comply with the study protocol for the duration of the study~* Informed consent/assent from the patient or from a parent or guardian in the case of children.~Exclusion Criteria:~* Presence of general danger signs in children aged under 5 years or signs of severe malaria according to the definitions of WHO~* Presence of severe malnutrition~* Acute anaemia \<8g/dL~* Regular medication, which may interfere with antimalarial pharmacokinetics~* History of hypersensitivity reactions or contraindications to any of the drug(s) tested or used as alternative treatment(s)~* A positive pregnancy test or lactating

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chloroquine primaquine 14days (Type: OTHER): P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
- artemether-lumefantrine primaquine 1day (Type: OTHER): P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
- artemether-lumefantrine primaquine 14days (Type: OTHER): mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants between the years of 18-65 with a diagnosis of PTSD (diagnosis can be made at screening)~Exclusion Criteria:~* Index trauma event \>15 years before screening~* Index trauma event at age \<16~* Any traumatic event within 3 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole + Sertraline (Type: EXPERIMENTAL): Participants were administered oral brexpiprazole initial dose of 0.5 milligram (mg)/day plus sertraline initial dose of 50 mg/day. The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo based on dose titration/adjustment up to Week 12.
- Brexpiprazole (Type: EXPERIMENTAL): Participants were administered oral brexpiprazole initial dose of 0.5 mg/day The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo up to Week 12.
- Sertraline (Type: ACTIVE_COMPARATOR): Participants were administered oral sertraline initial dose of 50 mg/day. The dose was up titrated to sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received brexpiprazole matching placebo and sertraline matching placebo based on dose titration/adjustment up to Week 12.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received oral brexpiprazole matching placebo tablet and oral sertraline matching placebo capsules up to Week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/= 18 years of age~* chronic hepatitis C~* informed consent to data collection~Exclusion Criteria:~* co-infection with HIV or HBV~* previous treatment with peginterferon and/or ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): Participants chronically infected with the hepatitis C virus including genotypes 1 to 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: includes presence of all the following:~* one or more clinical symptoms (persistent cough, recurrent hemoptysis, weight loss, malaise, fever and dyspnea) for ≥3 months~* slowly progressive or persistent radiological findings (one or more cavities and surrounding fibrosis, infiltrates, consolidation, with or without fungal ball or progressive pleural thickening) on computed tomography (CT) of the thorax~* immunological (A.fumigatus-specific IgG \>27 mgA/L or positive Aspergillus precipitins) or microbiological evidence of Aspergillus infection (growth of Aspergillus in respiratory secretions or serum galactomannan index \>0.5 or BALF galactomannan index \>1) and,~* exclusion of other pulmonary disorders with similar presentation.~Exclusion Criteria:~* failure to provide informed consent~* patients on immunosuppressive drugs, intake of prednisolone (or equivalent) \>10 mg for at least 3 weeks or a diagnosis of human immunodeficiency virus syndrome~* intake antifungal azoles for \>3 weeks in the preceding six months~* subjects with active pulmonary infection due to mycobacterium tuberculosis or mycobacteria other than tuberculosis (MOTT)~* subjects with others forms of pulmonary aspergillosis (allergic bronchopulmonary aspergillosis, chronic necrotizing aspergillosis and angio-invasive aspergillosis)~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Six months (Type: ACTIVE_COMPARATOR): Six months of itraconazole
- 12 months (Type: EXPERIMENTAL): 12-months of itraconazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* On peritoneal dialysis at least 3 months with a Kt/V of ≥ 1.7~* Use of Automated Peritoneal Dialysis~* Serum phosphate \> 5.5 mg/dL or \<5.5 mg/dL on a binder other than velphoro~* Serum albumin ≤ 3.7 g/dL~* Able to provide consent~* Ability to complete self-reported questionnaire~Exclusion Criteria:~* Inadequate dialysis~* Current use of sucroferric oxyhydroxide~* Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 6 months~* Active malignancy~* Recent episode of peritonitis~* Pregnancy or planning to become pregnant~* Anticipated kidney transplantation within 6 months~* Factors judged to limit adherence to interventions~* Known adverse side effect to sucroferric oxydroxide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diabetic nephropathy, type 1 diabetes, hypertension~Exclusion Criteria:~* child bearing potential, non-diabetic kidney disease, malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients 18-65 years of age, inclusive.~* A diagnosis of MDD, single episode or recurrent, according to DSM-IV-TR (296.2/296.3) with a current Major Depressive Episode of less than two year's duration with a minimum duration of at least 4 weeks.~* HAM-D score ≥ 22.~* HAM-D item 1 (depressed mood) score ≥ 2.~* Patients must be able to provide written informed consent to participate before beginning any trial related activities.~* Patients must be able to speak, read and understand English and possess the ability to respond to questions and follow simple instructions.~Exclusion Criteria:~* A current (or within 6 months prior to the Screening Visit) Axis I disorder of Post Traumatic Stress Disorder, Eating Disorder, Obsessive Compulsive Disorder (Generalized Anxiety Disorder, Social Phobia or Simple Phobia will be allowed).~* A history of schizophrenia, schizoaffective disorder or bipolar I or II disorder (with a history of hypomanic or manic episodes).~* DSM-IV-TR criteria for substance abuse (alcohol or drugs) within 3 months prior to Screening Visit or substance dependence within 6 months prior to the Screening Visit.~* Criteria for any of the following DSM-IV-TR MDD Specifiers: \[a\] With Catatonic Features; \[b\] With Postpartum Onset; \[c\] With Seasonal Pattern.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): vilazodone
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has facial acne vulgaris with:~  * 20 to 50 inflammatory lesions (papules, pustules, and nodules);~ * 25 to 100 noninflammatory lesions (open and closed comedones);~ * no more than 2 nodules on the face; and~ * IGA score of moderate (3) to severe (4)~* Willing to use only the supplied non-medicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study~Exclusion Criteria:~* Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne) or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations~* Sunburn on the face~* Severe systemic disease, which might interfere with the conduct of the study or the interpretation of the results.~* Abnormal baseline laboratory values that are considered clinically significant~* Allergy to tetracycline-class antibiotics or to any ingredient in the study drug~* Pseudomembranous colitis or antibiotic-associated colitis

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX-101, 4% minocycline foam (Type: EXPERIMENTAL): Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
- Vehicle foam (Type: PLACEBO_COMPARATOR): Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated GFR \< 45 ml/min/1.73m2 and \>15 ml/min/1.73 m2 determined by abbreviated 4 variable modification MDRD equation~* Age \>21~Exclusion Criteria:~* Previous chronic treatment with alkali (including sodium bicarbonate, calcium carbonate or baking soda)~* Bicarbonate level \<20 or \>25 mEq/L~* Decompensated heart failure~* Systolic blood pressure \>160 mm/Hg~* Moderate or greater lower extremity edema~* Initiation of ESRD treatment planned within 6 months~* Kidney transplantation~* Treatment with immunosuppressives within the last 3 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium Bicarbonate (Type: ACTIVE_COMPARATOR): Sequential design. Participants will be getting different doses of sodium bicarbonate during the study.
- Placebos (Type: PLACEBO_COMPARATOR): Sequential design. Participants will be getting either placebo of different doses during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Disease must be clinically limited to the esophagogastric junction, defined TypeⅡ TypeⅢ(From the endoscopic point of view according to the AEG criteria)~2. Histologically confirmed primary adenocarcinoma~3. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3M0，~4. ECOG performance status ≦2~AEG is defined and described as tumors which have their center within 5cm proximal or distal of the anatomical cardia.~The classification of AEG type I, type II and type III AEG type I: adenocarcinoma of the distal esophagus,which usually arises from an area with specialized intestinal metaplasia of the esophagus, i Barrett's esophagus, and may infiltrate the esophago-gastric junction from above;~* AEG type II: true carcinoma of the cardia, arising from the cardia epithelium or short segments with intestinal metaplasia at the esophago-gastric junction;~* AEG type III: subcardial gastric carcinoma, which infiltrates the esophago-gastric junction and distal esophagus from below.~Exclusion Criteria:~1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy, endoscopic ultrasound and CT scanning.~2. Patients with primary carcinomas of the esophagus.~3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past 5 years, or prior esophageal or gastric surgery.~4. Patients with evidence of metastatic disease are not eligible.~5. Patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication.~6. Patients who cannot fully comprehend the therapeutic implications of the protocol or comply with its requirements.~7. Patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study.~8. History of hypersensitivity to fluoropyrimidines, capecitabine, oxaliplatin or the ingredients of this product -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- postoperative chemotherapy,XELOX (Type: ACTIVE_COMPARATOR): None
- Preoperative Concurrent Chemoradiotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete